Sanofi’s $1 Billion Bet on Muscular Dystrophy Drug Falters, Fulcrum Shares Plummet

Sanofi's Investment:
Sanofi had invested $1 billion in a muscular dystrophy drug developed by Fulcrum Therapeutics.

Clinical Setback:
The drug has faced significant clinical setbacks, leading to a decline in Fulcrum's stock value.

Market Impact:
Fulcrum's shares have nosedived following the news, reflecting the high stakes and risks associated with pharmaceutical investments.

Pharmaceutical Challenges:
The failure highlights the challenges in developing effective treatments for complex diseases like muscular dystrophy.

Financial Consequences:
The failure of the drug could have significant financial implications for both Sanofi and Fulcrum Therapeutics.